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Hypoglycaemia-Associated Counter-RegulationAdhithya Sankar,1 Tansi Khodai,1 Alison D. McNeilly,2 Rory J. McCrimmon,2 and Simon M. Luckman1,*Highlights
Impaired awareness of hypoglycaemia
(IAH) is a common and poorly under-
stood complication of insulin-treated
diabetes and evolves following repeated
episodes of hypoglycaemia.
An improved mechanistic understanding
of IAH is required and necessitates a
robust diseasemodelwithwhich to inter-
rogate changes within the glucose-
regulatory network.
A large variety of experimental models
have been outlined, leading to a lack
of consensus among investigators in
this field. Appreciating the influence of
experimental parameters and physio-
logical differences on findings can aid
progress in the field.Impaired awareness of hypoglycaemia (IAH) affects around a quarter of patients
with diabetes who receive insulin treatment. This condition is characterised
by a progressive reduction in symptomatic and behavioural responses to
hypoglycaemia, increasing risk of deeper drops in blood glucose, unconsciousness,
and collapse. Thus, patients with IAH experience severe hypoglycaemic episodes
more frequently, resulting in significantmorbidity andmortality. IAH is thought to de-
velop as a consequence of whole-body adaptations to repeated insulin-induced
hypoglycaemia (RH), with widespread deficits in the hypoglycaemia counter-
regulatory response (CRR). Despite this important insight, the precise patho-
physiology by which RH leads to an attenuated CRR is unknown. Studies into
the underlying mechanisms of IAH have employed a variety of protocols in
humans and experimental species. The use of animal models hasmany investiga-
tional benefits, including the unprecedented increase in the availability of trans-
genic strains. However, modelling impaired hypoglycaemia-associated counter-
regulation remains challenging and appropriate interpretation of findings across
species and protocols even more so. Here, we review the experimental modelling
of IAH and impaired hypoglycaemia-associated counter-regulation, with a focus
on understanding species-specific variation in glucose homeostasis. This
review will aid investigators in interpreting outputs from different studies in IAH
and aid progress in the field.1Faculty of Biology, Medicine and
Health, University of Manchester,
Manchester, UK
2Division of Systems Medicine, School




(S.M. Luckman).Hypoglycaemia Counter-Regulation and IAH
For individuals with diabetes, hypoglycaemia (see Glossary) is a relatively common adverse
effect of insulin therapy, occurring as frequently as twice per week in those with type 1 diabetes
[1,2]. Hypoglycaemia leads to both acute and chronic multisystemic effects, causing significant
morbidity, mortality, and distress to patients [1]. The increased propensity for hypoglycaemia
occurs in patients with type 1 diabetes and long-duration type 2 diabetes in a setting of markedly
altered glucose homeostasis. First, pancreatic β cell destruction or decline necessitates insulin
administration which, despite advances, is normally delivered as a subcutaneous (SC) depot at
supraphysiological doses. This leads to relative systemic hyperinsulinaemia, increasing peripheral
uptake of glucose and, therefore, the risk of hypoglycaemia. Crucially, exogenous insulin is not
then supressed, as would normally occur when the blood glucose falls below 4.4 mmol/l [3].
Second, in patients with type 1 diabetes, α cell dysfunction develops, impairing normal glucagon
release. This deficit affects most patients within 5 years of disease diagnosis [4]. This places a
greater reliance on the sympathoadrenal system and adrenaline release for hypoglycaemia-
induced CRR (Box 1) [5]. Subsequently, the loss of glucagon and sympathoadrenal system
responses is closely correlated with the loss of symptom responses, leading to IAH.
IAH is highly prevalent, affecting around 25%of patients undergoing insulin treatment for diabetes
[8]. Individuals with IAH have a sixfold increased risk of severe hypoglycaemia, leading to
acute and chronic health sequelae [8]. However, identifying patients with IAH can be tricky, asTrends in Endocrinology & Metabolism, September 2020, Vol. 31, No. 9 https://doi.org/10.1016/j.tem.2020.05.008 691
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Glossary
Counter-regulatory response
(CRR): the stepwise autonomic and
neuroendocrine mechanisms that act
during hypoglycaemia to restore normal
blood glucose (Box 1).
Hypoglycaemia: blood glucose of less
than 3.9 mmol/l with (documented





ability to perceive the onset of
hypoglycaemia.
Box 1. The Normal Response to Falling Blood Glucose Levels
In healthy individuals, a fall in blood glucose initiates a CRR. This takes the form of hormone release or inhibition, as well as
symptom awareness, prompting appropriate behaviours (see Figure 1 in main text). If the blood glucose falls below 4.5
mmol/l, endogenous insulin secretion is inhibited. This is mediated not only through peripheral mechanisms, but through
supplementary control from the brain [6]. This reduces glucose uptake by nonneuronal tissues and for most individuals is
sufficient to maintain their blood glucose in the normal range. However if the blood glucose falls below 3.8 mmol/l, the glu-
cose-sensing network in the central nervous system initiates a hormonal CRR [7]. This includes glucagon release from
pancreatic α cells and adrenaline release from the adrenal gland chromaffin cells [7]. This is soon followed by
hypoglycaemia autonomic symptoms (see Figure 1B in main text), which are a vital response for individuals with diabetes.
Autonomic symptoms primarily arise from sympathoadrenal system activity and develop at a glucose level of ~3.2 mmol/l
[3]. They lead to awareness and a prompt behavioural response from the individual (carbohydrate ingestion or to seek as-
sistance) before cognitive dysfunction and neuroglycopenia occurs at ~2.7 mmol/l [3]. Thus, individuals who retain symp-
tom awareness of hypoglycaemia are able to take action before cerebral dysfunction occurs.
Trends in Endocrinology &Metabolismhypoglycaemia symptoms are subjective and can be present or absent to varying degrees [9].
Hypoglycaemia symptoms can be categorised into three groups: autonomic, neuroglycopaenic,
and malaise [10]. Autonomic symptoms (Figure 1B) are a result of increased sympathoadrenal
activity (endocrine adrenaline release and sympathetic neural activity). They occur at blood glucose
levels of ~3.2 mmol/l and serve to ‘raise the alarm’, prompting a behavioural response
(food ingestion). In their absence, blood glucose levels may decrease further, precipitating
neuroglycopaenia. Neuroglycopaenic symptoms (Figure 1B) occur due to brain depletion of
glucose and become apparent at blood glucose levels of ~2.7 mmol/l. In IAH, autonomic symptom
impairment can be explained by the seminal discovery that antecedent hypoglycaemia leads to a re-
duced adrenaline response, as well as symptoms, to subsequent hypoglycaemia [11]. Repeated
hypoglycaemia (RH) lowers the glycaemic threshold at which both autonomic and neuroglycopaenic
symptoms are perceived. Ultimately, neuroglycopaeniamay occur first, preventing the recognition of
autonomic symptoms [12]. Therefore, RH is likely to be an important driver of IAH in diabetes, leading
to altered magnitude and threshold of the sympathoadrenal response.
Unfortunately, traditional treatment options for IAH have limited efficacy and are often to
the detriment of controlling the underlying diabetes. Achieving an effective treatment for IAH,
it can be argued, will first require a greater understanding of IAH at a mechanistic level.
Establishing the specific effects of RH on the whole-body glucose-regulatory network requires
robust models.
Experimental Approaches to Investigate IAH
Following the seminal work that identified that two prior hypoglycaemic episodes lead to
diminished sympathoadrenal and symptom responses to subsequent hypoglycaemia, human
(Box 2) and animal studies have adapted this experimental design in a number of ways to more
fully investigate IAH [13–16].
Measuring IAH and the Impaired Hypoglycaemia CRR
Central to the investigation of IAH has been the search for a robust measure for impaired
hypoglycaemia CRR and/or IAH. The use of symptom scores such as the Edinburgh
Hypoglycaemia Scale allows a degree of quantification of hypoglycaemia awareness [8].
Symptom scores are limited in that they are culturally specific and vary based on subjec-
tive interpretation and prior experiences. In addition, symptom responses are affected by
experimental conditions, particularly when measured in a highly controlled laboratory
environment and following overnight fasting. Also, it can be argued that symptom scores
do not fully encompass the magnitude of impairment of the CRR with RH. Therefore,
biological markers of IAH and impaired CRR may have more utility, allowing greater comparison
between studies.692 Trends in Endocrinology & Metabolism, September 2020, Vol. 31, No. 9
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Box 2. Investigating IAH in Humans
In humans (both healthy individuals and patients with diabetes), RH-related changes are always studied with the aid of
hypoglycaemic–hyperinsulinaemic clamps. This technique ensures that blood glucose levels are maintained at a desired
threshold and, importantly, ensures safety. The aim in human studies of IAH is to expose subjects to either a SH or multiple
antecedent episodes of hypoglycaemia on the first day, followed by a subsequent SH episode on the following day.
Counter-regulatory hormones (adrenaline, glucagon, and corticosterone) and hypoglycaemia symptom scores are
measured following both the antecedent and the subsequent hypoglycaemia to allow IAH and the impaired CRR to be
characterised [13–16].
In humans, neuroimaging modalities have been employed to investigate changes in brain activity, metabolism, and blood
flow following SH and RH, providing insights into hypoglycaemia-responsive brain regions [17]. Interestingly, other
measures of nervous system changes have also been studied, identifying decreased baroreflex sensitivity and muscle
sympathetic nerve activity following two episodes of antecedent hypoglycaemia [16]. These data support the hypothesis
that the effects of antecedent RH are on multiple arms of the nervous system. This generalised effect of RH on the
autonomic and neuroendocrine systems is also demonstrated by the finding that comparable impairments of hormonal
and symptom responses are seen in individuals both with and without diabetes [11,15,18]. In addition, this hints that
the changes that follow RH are not specific to the pathophysiology of diabetes, but rather a reflection of whole-body
adaptation to the repeated stress of hypoglycaemia.
A major limitation of studies in diabetic subjects and in patients with IAH is that it is not known whether unidentified
hypoglycaemia episodes have occurred prior to the beginning of the study. As a result, glucose-regulatory network
changesmay already be present to a varying degree prior to the study, affecting findings. Despite these limitations, human
studies have provided important insights into the organisation of the glucose-regulatory network and the hypoglycaemia
CRR. However, to enable more detailed mechanistic and cellular understanding of the pathophysiology of IAH, animal
models are required.
Trends in Endocrinology &MetabolismAt a mechanistic level, there is consensus in the field that impaired sympathoadrenal responses and
loss of glucagon secretion largely account for the loss of symptomatic awareness that characterises
IAH [19]. The sympathoadrenal network comprises sympathoneural and adrenomedullary
components, which are both impaired with RH. With hypoglycaemia, both arms of the
sympathoadrenal system are activated, although it has been suggested that the sympathoneural
system is capable of generating autonomic symptoms of hypoglycaemia, even in the absence
of a functioning adrenomedullary system [20]. Hypoglycaemia-related symptoms and counter-
regulation are mediated through the effects of catecholamines, particularly adrenaline and
noradrenaline. These catecholamines normally increase in parallel following hypoglycaemia, such
that plasma levels of adrenaline and noradrenaline are highly correlated [20]. However, in rats,
insulin-induced hypoglycaemia may preferentially stimulate adrenomedullary cells producing
adrenaline compared with those producing noradrenaline [21]. Similarly, both central and systemic
glucoprivation with 2-deoxyglucose (2DG) treatment in rats increases adrenaline secretion
preferentially over noradrenaline [22–24]. This detail may be species related or due to difficulties
in detecting differences in plasma noradrenaline [25]. Therefore, adrenaline in concert with
noradrenaline leads to potent glucose-raising effects, which, in the setting of deficient glucagon
release, are vital for patients with type 1 diabetes.
Quantification of the sympathoneural response is possible by measuring noradrenaline spill over
from synaptic release into the circulation. However, this technique may underestimate sympa-
thetic activation, as the majority of the released noradrenaline is dissipated locally by reuptakeFigure 1. Hormone and Behavioural Responses to Falling Blood Glucose. (A) Stepwise hypoglycaemia and
thresholds for each counter-regulatory response (CRR) in humans. (B) Autonomic, neuroglycopaenic (shortage of glucose
in the brain due to hypoglycaemia), and malaise symptoms. Normally, autonomic symptoms are initiated, thereby raising
awareness of hypoglycaemia. However, in patients with impaired awareness of hypoglycaemia (IAH), thresholds are
dangerously altered, with neuroglycopaenic symptoms and injury occurring before autonomic symptoms (which are often
absent altogether) [3,10,76,96].
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activation sufficient to produce biological effects may not be reflected by a concomitant rise in
plasma noradrenaline [27]. This has been demonstrated for hypoglycaemia thresholds, which
must be markedly reduced (b2 mmol/l) before increases in pancreatic noradrenaline are detected
[27]. Thus, the relative ease and accuracy of measuring plasma adrenaline, compared with
noradrenaline, makes it the best biomarker for RH-related impaired glucose-counter regulation
and IAH [28].
Glucagon, which is the other major counter-regulatory hormone, also is measured consistently in
studies investigating IAH. RH leads to attenuation of glucagon release in a subsequent episode of
hypoglycaemia in most nondiabetic human studies [17,18,29,30]. However, the relevance of this
in the context of IAH is diminished, as glucagon release ceases within 5 years of diagnosis in most
patients with type 1 diabetes. This glucagon deficit appears to occur through a mechanism
distinct from the RH effect on catecholamine responses [31]. Therefore, patients with type 1
diabetes may develop attenuated glucagon release before IAH develops. This reiterates the
importance of the sympathoadrenal response in people with diabetes who have IAH [32].
Cortisol (corticosterone in rodents), the major ‘stress’ hormone, also increases following
hypoglycaemia [33]. In general, in humans, antecedent insulin-induced hypoglycaemia attenuates
cortisol release in a subsequent episode of hypoglycaemia [14,17,32,34,35]. However, this is
not a universal finding and other investigators have reported no change in cortisol release with
RH [30]. Hypothalamopituitary–adrenocortical (HPA) axis activation typically occurs as the blood
glucose falls to b3.7 mmol/l; however, the effects of cortisol on blood glucose are delayed. Using
a pancreatic-adrenocortical-pituitary clamp to maintain basal cortisol levels, De Feo et al. demon-
strated that a lack of cortisol rise resulted in lower rates of glucose production and higher rates of
glucose utilisation only after 6 h in nondiabetic humans (glucagon, insulin, and growth hormone
were infused to maintain similar plasma concentrations in the two groups) [36]. In addition,
cortisol-deficient patients only begin to display reductions in plasma glucose (compared with
controls) 2.5 h after insulin-induced hypoglycaemia [37]. These findings suggest that the
counter-regulatory effects of cortisol are more relevant during prolonged hypoglycaemia, which
patients often encounter while asleep [38]. Equally important is that HPA axis activation
does not initiate hypoglycaemia-symptom awareness. Therefore, it can be argued that cortisol/
corticosterone measurement in studies relating to IAH is also of minor relevance.
Animal Models of Loss of Hypoglycaemia-Associated Counter-Regulation
Studying the condition of IAH using animal models provides several advantages to investigators.
Using experimental tools, RH-related changes at a tissue and cellular level can be observed. This
is particularly true for studies relating to the central nervous system, which may hold the key to
understanding IAH. Animal studies also allow glucose counter-regulation to be measured at a
wider range of glucose levels and under more controlled experimental conditions. Last, therapeutic
discovery requires an effective animal model prior to consideration for human intervention. Among
the animal species studied, rats are most commonly encountered in IAH research, with fewer
mouse studies published.
In rodent studies, investigators have modified human experimental protocols of RH to investigate
CRR changes. These protocols, which involve between one and 12 antecedent insulin-induced
hypoglycaemia episodes, demonstrate that, in rodents, impairments of the CRR can be achieved
analogous to the human phenomenon [25,39–57]. This is particularly true for plasma adrenaline
and, in general, for plasma corticosterone, although a small number of studies have reported
no effect of RH on plasma corticosterone release [52,53]. Similarly, there are inconsistenciesTrends in Endocrinology & Metabolism, September 2020, Vol. 31, No. 9 695
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in both human and mouse studies [13,14,17,29,30,35,58–62]. As impairment of the
sympathoadrenal response and adrenaline release is considered the best marker for IAH
and impaired counter-regulation, this suggests that rodent models can provide a good represen-
tation of the human condition. One notable problem is that identifying and recording awareness is
much more difficult than in human studies of IAH. Otlivanchik et al. have used conditioned place
preference (CPP) behaviour, and its loss with single hypoglycaemia (SH), as a surrogate measure
of hypoglycaemia awareness. In their model CPP is first induced by giving rats a reward to induce
place preference. The CPP is blunted with the negative perception of SH, reversing the reward
conditioning. However, if the rats first undergo RH, they are no longer ‘aware’ of the negative
valency of a subsequent hypoglycaemic episode and the CPP is preserved [63]. As our under-
standing of animal behaviours improves, more direct hypoglycaemia symptom measures may be
identified, allowing more accurate modelling of the clinical condition.
In rats, not all protocols utilise insulin to study RH-related changes. In some studies, insulin is
substituted or occasionally combined with repeated injections of 2DG, a strong glucoprivic
agent [57,64,65]. Consistent with human studies, rodents exposed to repeat insulin-induced
hypoglycaemia and then perfused with 2DG intracranially, demonstrate significant suppression
of the CRR [66]. However, 2DG causes an increase in peripheral glucose and has numerous
intracellular effects independent of inhibiting glucose metabolism [67].
From rat studies, we can gather that, despite differences in protocols, many groups have
achieved attenuation of the adrenaline response following RH, the key marker of successful
modelling of the disease [25,39–41,43,44,46,47,50–52,54,68]. A recent protocol outlined by
the McCrimmon laboratory to study IAH and RH-related counter-regulatory impairment in
rats, used intraperitoneal (IP) insulin (0.75–1 units/kg, Novorapid) or volume-matched IP saline
injections administered three times weekly for 4 weeks. The chronicity of the protocol,
combined with its validation in a type 1 diabetes animal model, make it more relatable to the
human condition. Crucially, use of this protocol significantly attenuated the adrenaline
response to subsequent hypoglycaemia, fulfilling the criteria for successful modelling of the
human condition [69].
For many groups, translation from rat models to the mouse has proved to be more difficult.
However, the development of a mouse model is of interest, as transgenic strains and recombi-
nant techniques enable unprecedented appreciation of pathways, including those implicated in
glucose homeostasis.
Poplawski et al. utilised a RH protocol involving daily IP insulin injections for 4 days before
comparing responses on the fifth day between the RH and a SH group. This protocol produced
attenuated glucagon and corticosterone release, but no impairment of the adrenaline response
to subsequent hypoglycaemia was noted [62]. In this study, hormones were measured from
truncal sampling 4 h after insulin injection, which is likely to have identified more delayed
hypoglycaemia-related hormone effects [62].
Experiments by a different group, in chronically cannulated wild-type and transgenic mice, have
examined hypoglycaemia CRR hormone release following a single prior hypoglycaemic episode.
In these experiments, mice received either a euglycemic or a hypoglycaemic clamp on day 1
and CRR hormone responses were measured following a subsequent hypoglycaemic clamp
on day 2. Antecedent hypoglycaemia significantly lowered glucagon but not adrenaline in both
experiments [61,70]. The authors in these studies have argued that all components of the CRR696 Trends in Endocrinology & Metabolism, September 2020, Vol. 31, No. 9
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only Ma et al. have been able to demonstrate diminished 24-h urinary adrenaline levels following a
4-day protocol of repeated IP insulin injection [65]. Truncal blood (plasma) adrenaline was closely
correlated with urinary adrenaline. However, this was not significantly attenuated with RH, but
was reduced with antecedent 2DG. This discrepancy raises the question of whether the acute
CRR to hypoglycaemia was truly impaired [65]. Therefore, a robust murine model is yet to be
described, although the Luckman laboratory has now replicated the 4-week protocol in mice
previously reported by the McCrimmon laboratory in rats [69].
Animal studies, and particularly those in rats, have been instrumental in investigations of
the mechanisms underlying IAH. However, they are not without their own disadvantages.
Species- and strain-specific physiological differences are underappreciated. In addition, animal
studies commonly lead to loss of biological variability, a result of using inbred strains and young
animals (often littermates) and restriction to a single sex. Other influential factors include the
need to control for handling and environmental stressors – particularly relevant when measuring
responses of the sympathoadrenal system [71].
Experimental Protocols and Parameters in IAH Studies
Important differences exist in how IAH and RH-related counter-regulatory impairment is achieved
between human and rodent studies. In humans, the general protocol for achieving impaired
CRR involves exposing subjects to one or two antecedent episodes of hypoglycaemia on the pre-
vious day, followed by a subsequent episode of hypoglycaemia [13,14,18,29,30,32,35,58–60,72].
Following an overnight fast, reductions in blood glucose to between 2.2 and 3.3 mmol/l, for about
1–2 h, are achieved utilising a hyperinsulinaemic–hypoglycaemic intravenous (IV) clamp. Venous
blood sampling allows the measurement of counter-regulatory hormones and symptom scores
are recorded [13,14,18,29,30,32,35,58–60,72]. However, direct translation of the above experi-
mental protocol to rodents has been demonstrated by only two independent groups, signifying
the challenges faced by investigators [46,49]. These difficulties may be explained by differences
in intrinsic inter- and intraspecies variation in glucose and CRR physiology, an area of research
that requires much greater attention (Box 3).Box 3. Interspecies and Interstrain Differences in Glucose Homeostasis and CRR
The BMR determines the glucose and energy requirements for an organism tomaintain body function. In relative terms, the
mouse has a BMR that is around 7.5 times greater than that of a human [73]. This is reflected by the finding that mouse
blood glucose levels are substantially higher than in humans and that the relative basal glucose turnover rate is 10–15 times
greater [74]. This increased glucose requirement is met, in part, by enhanced gluconeogenesis. Corresponding with the
enhanced BMR and glucose turnover, mice have higher endogenous insulin production than rats and humans [74]. Mice
and humans display more similarities with respect to hormone thresholds. In particular, thresholds for glucagon secretion
in response to insulin-induced hypoglycaemia are comparable [75]. However, in mice the glucose threshold for an increase
in plasma adrenaline and corticosterone is around 4.4mmo/l [61]. This is higher than the 3.3–3.9-mmol/l glucose threshold
reported in nondiabetic humans [76]. Precise hormone release thresholds have not been identified in rats. However,
it is evident that rats demonstrate significant increases in adrenaline, glucagon, and corticosterone when
hypoglycaemia ~3.2 mmol/l is achieved, paralleling the nondiabetic human condition [25,39–57].
The assessment of strain-dependent metabolic variance has been performed more extensively in mice than in rats. In the
latter, background strain effects have been more frequently studied in the context of experimental obesity. Here, even
in the commonly used Wistar and Sprague–Dawley rats, diet-induced obesity and insulin resistance susceptibility vary
considerably [77]. In mice, baseline glucose production and turnover and endogenous insulin secretion have been shown
to differ between commonly used mouse strains (ICR, FVB/N, 129X1/Sv, and C57BL/6) [78]. Following insulin-induced
hypoglycaemia, adrenaline release was increased in C57BL/6, FVB/N, and DBA/2 mice but was below the limits of
detection in 129X1/Sv mice [79]. Glucagon release to hypoglycaemia was similarly blunted in 129X1/Sv mice, while
corticosterone release was transiently elevated in DBA/2 mice but did not increase in C57BL/6, 129X1/Sv, and FVB/N
mice [79]. This nicely highlights that background strain, as well as species, can significantly alter hypoglycaemia counter-
regulation, which will directly impact CRR hormone levels following RH.
Trends in Endocrinology & Metabolism, September 2020, Vol. 31, No. 9 697
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shown in Table 1. We now consider how differences in RH protocol parameters, along with
species-specific differences in physiology, influence CRR output measures.
Depth and Number of Antecedent Hypoglycaemia Episodes
The use of antecedent hypoglycaemia depths of b2.0 mmol/l (profound hypoglycaemia) is also
encountered in the literature, although this degree of hypoglycaemia, which is often associated
with multiple seizures, is of debatable relevance to the human condition and may lead to irreversible
changes [25,39,41,46,49,52,53]. In humans, the antecedent hypoglycaemia depth has been shown
to influence both themagnitude and the pattern of CRR. Davis et al. reported segregation of patterns
of hormone attenuation depending on the depth of antecedent hypoglycaemia in humans. Specifi-
cally, hypoglycaemia of 3.9mmol/l during antecedent episodes led to reduced plasma adrenaline
and glucagon responses to subsequent hypoglycaemia, whereas with blood glucose levels of
b3.3mmol/l a more significant reduction in glucagon, adrenaline, noradrenaline, and growth
hormone responses occurred following subsequent hypoglycaemia [80]. Interestingly, there was
no additional impairment in the counter-regulatory hormone response when the antecedent
hypoglycaemia depth was reduced further, from 3.3 to 2.9 mmol/l. This suggests that there is a
hierarchy of counter-regulatory hormone impairment, which depends on the depth of the ante-
cedent hypoglycaemia. Whether this hierarchy continues with antecedent hypoglycaemia
depths b2.9 mmol/l is unknown [80].
In humans, the duration of antecedent hypoglycaemic episodes also affects the pattern of
counter-regulatory impairment. Of note is that short (5 min), intermediate (30 min), and prolonged
(90 min) antecedent hypoglycaemic episodes all produced impairments comparable with
counter-regulatory hormones [81]. However, autonomic symptoms were blunted significantly
only by intermediate- or prolonged-duration hypoglycaemia [81]. If these observations translate
to animals, hypoglycaemia durations of between 30 and 90 min should also attenuate CRR in
animals. Most successful animal studies employ durations of between 60 and 180 min of
hypoglycaemia in their protocols [25,39–57].
There is evidence to support greater impairment of hypoglycaemia counter-regulation when the
number of antecedent hypoglycaemic episodes is increased in humans [34,80,82]. Similarly, inTable 1. Summary of Experimental Protocols for RH-Related Impaired CRR in Humans, Rats, and Micea





















40 min to 2 h
(majority of
studies)
3 h (one study)
2.2–3.3 mmo/l
(all studies)
1/day for 1 day
2/day for 1 days
(majority of studies)




























1/day for 1 day
1/day for 2 days
1/day for 3 or 4 days
2/day for 1 day
Three times per




IP and IV 2.5 units/kg
20 mU/kg/min
3–6 h Central venous
Tail
2–3 h duration 2.2–3.8
mmol/l
1/day for 4 days
1/day for 1 day
[61,62,65,70]
aHuman studies include those undertaken in healthy volunteers and patients with diabetes. Animal studies include those undertaken in transgenic strains and diabetes
animal models.
bAbbreviation: ICV, intracerebroventricular.
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nonrecovery in the animals. This is reflected in adaptations of protocols such that, as the protocol
progresses, the dose of insulin is reduced [69,83]. In our hands, in a 4-week RH protocol where
mice receive three insulin injections per week for 4 weeks, there is a greater duration and depth of
hypoglycaemia with successive antecedent hypoglycaemic episodes. In rats, after 3 weeks of
this RH protocol, the dose of insulin is decreased by 25% to prevent the development of severe
hypoglycaemia requiring rescue [69]. Interestingly, the effect of two antecedent hypoglycaemic
episodes on the same day, compared with one, does not seem to produce a greater attenuation
in adrenaline release on subsequent hypoglycaemia in rats [84]. Therefore, if IAH represents a
form of neuronal adaptation such as habituation, an effect may be encountered only with a
greater number of hypoglycaemia episodes and by allowing more time between episodes for
cellular modification.
Induction of Hypoglycaemia
Repeated insulin-induced hypoglycaemia is accepted as the best model for studying IAH.
Although protocols with 2DG-induced glucoprivation exist, this approach does not fully repli-
cate the human condition, where iatrogenic insulin (combined with inherent diabetes-related
counter-regulatory deficits) causes hypoglycaemia. In human studies, insulin is administered
via IV infusion at a dosage of 1–2 mU/kg/min, without exception. However, in animal
studies that utilise IV insulin infusion, dosages of 20–50 mU/kg/min are utilised commonly
[41,42,44,45,48,51]. Direct translation of insulin dosage to animals is understandably not
possible. However, extreme hyperinsulinaemia, out of proportion to levels witnessed in the
human condition, may fundamentally alter physiological responses. Insulin itself can affect
the CRR to hypoglycaemia, including modulation of the sympathoadrenal response to
hypoglycaemia by shifting glucose-sensing neuron thresholds [85–87]. Also, it has been
suggested that hyperinsulinaemia alters the glucagon response to hypoglycaemia in non-
diabetic and diabetic humans [3,88,89]. Therefore, to minimise the effect of hyperinsulinaemia
on the interpretation of the CRR, it is advisable to utilise the lowest insulin dosage that elicits
consistent hypoglycaemia in the chosen protocol.
Animal studies in the field of IAH also employ routes of insulin administration other than IV,
including the use of IP and SC injections. The IV route provides advantages in ensuring that
precise target hypoglycaemia levels and durations are reached, while providing vascular access
for blood sampling and replacement. The IV route is limited in that it can result in stress to animals
from surgical implantation. In addition, the procedure makes it complex to prepare large cohorts
for investigations. As a result, IP and SC routes are commonly selected due to the ease of
administration without the need for prior surgery. There remains a lack of consensus over whether
IP or SC insulin produces the more consistent duration and intensity of hypoglycaemia. Flanagan
et al. report that the IP route wasmore consistent in their experience; however, other investigators
have used SC insulin with good effect [39,40,90]. The IP route increases the risk of injection into
the bowel, leading to potential complications and variable delivery of insulin. In the Luckman
laboratory, we have found that the SC route can reliably lower blood glucose in a reproducible
manner in mice on the C57BL/6 background, leading to a subsequent diminished adrenaline
response (S.M. Luckman et al., unpublished). In addition, the SC route replicates how patients
administer insulin therapy.
It is known that the administration route directly influences pharmacokinetics. In humans,
IV infusion causes significantly higher serum insulin levels than the same dose through SC
administration, and SC insulin takes up to four times longer to return to baseline levels
[91]. Therefore, the route of administration can alter the bioavailability, affecting the depthTrends in Endocrinology & Metabolism, September 2020, Vol. 31, No. 9 699
Outstanding Questions
What is the cellular mechanism by which
repeated exposure to hypoglycaemia
leads to IAH development?
Where in the glucose-regulatory
network does the pathophysiological
process occur?
Does glucagon dysfunction in type 1
diabetes alter the glucose-regulatory
network and the sympathoadrenal
response?
Can we develop a robust measure
to assess hypoglycaemia symptoms
in animals, thereby allowing a direct
measure of hypoglycaemia awareness
in the setting of RH?
Trends in Endocrinology &Metabolismand duration of hypoglycaemia, resulting in variation in counter-regulatory hormone release
and impairments following RH [91].
Overnight fasting is the established procedure prior to insulin-induced hypoglycaemia in human
studies. In animal studies, investigators use a variety of approaches, including prior overnight
fasting [41,45,46,48], fasting for 1–6 h [43,61,62], and even no fasting [25,39,40,47,49,54]. Fasting
prior to insulin-induced hypoglycaemia increases tissue sensitivity to insulin and lowers the baseline
serum glucose, reducing the total insulin dose requirements to induce hypoglycaemia [87]. In mice,
insulin sensitivity increases when the duration of fasting is increased [88]. This may improve the
ability to detect hypoglycaemia-specific changes to counter-regulation by limiting the effects of
hyperinsulinaemia. However, care must be taken over the duration of fasting. Rodents consume
most of their energy requirements during the dark phase of the day–night cycle, which means
that overnight fasting is an intense metabolic stressor. Following overnight fasting, rodents deplete
liver glycogen stores rapidly, requiring increased de novo glucose production [88]. This, in combi-
nation with increased insulin-stimulated glucose transport, leads to altered counter-regulatory
hormone levels with overnight fasting [88]. In mice, fasting (overnight/N16 h) significantly increases
corticosterone and autonomic drive, enhancing glucose production to maintain the basal
metabolic rate (BMR) [89,90]. Fasting will, therefore, affect baseline adrenaline and corticosterone,
although this is unlikely tomask hypoglycaemia-related increases in these hormones. After 16–18 h
of fasting, mice move into a catabolic state, losing significantly more total body, lean, and fat
masses than with 5-h fasting [88]. This differs to humans, where prolonged fasting impairs
insulin-stimulated glucose utilisation [88]. Thus, in the investigation of responses to RH, overnight
fasting may prove to be an excessive stress stimulus and potentially confound findings.
In our laboratory, we routinely fast for 3 h prior to inducing hypoglycaemia, which we have found
to reduce baseline glucose and variability between mice.
Considering the diversity of protocols and CRR measures, the focus should remain on ensuring
that experimental methods demonstrate a consistent impairment of the sympathoadrenal
response following RH. This is the central feature, whichwe argue demonstrates a robust disease
model. However, the model must control for other repeated stressors encountered, to ensure
that the impaired sympathoadrenal response is specific to RH. Differences in model parameters,
such as route, fasting duration, hypoglycaemia duration, and even the number of antecedent
episodes, may be less relevant.
Although IAH and impaired CRR can be modelled in nondiabetic rodents and humans, the
findings should ultimately be replicated in the setting of diabetes to ensure translational rele-
vance. This poses additional challenges, which are explored in Box 4. In IAH research, only a
few groups have utilised diabetic animal models for their investigations [55,56,92,93]. Here,
as in nondiabetic IAH studies, a greater uniformity of approach may enable better comparisons
between studies.
Concluding Remarks and Future Perspectives
In this review, we have outlined the challenges faced by investigators in creating a model to study
IAH and impaired CRR. Differences in experimental protocols and species and strain variations
between studies lead to difficulty in interpreting findings. Here, we have examined the effect of
these differences on the CRR and sympathoadrenal response. We argue that the demonstration
of the core feature of IAH – namely, impaired plasma adrenaline release – signifies a robust IAH
disease model. However, with improved understanding of animal behaviours, it may be possible
to identify a direct measure for hypoglycaemia symptoms as well. Despite these challenges,700 Trends in Endocrinology & Metabolism, September 2020, Vol. 31, No. 9
Box 4. Animal Models of Type 1 Diabetes in IAH Research
A number of diabetic animal models have been identified to allow the study of type 1 diabetes [93]. Here, the main goal is to
demonstrate β cell destruction or failure. This can be achieved through a variety of methods, including chemical destruc-
tion of β cells, spontaneous autoimmunity through breeding, and genetically induced mechanisms [94]. Streptozotocin-
induced diabetes is the most common, chemically induced type 1 diabetes model. It is a simple and cheap method,
achieving a high percentage of destruction of β cells [94]. Its major limitation is that the magnitude of β cell destruction
can be variable, affecting the severity of insulin deficiency and the resultant diabetes [94]. Unfortunately, insulin mainte-
nance treatments are often not instituted in streptozotocin-induced diabetes experiments, which means that animals
are both hypercatabolic and hyperosmotic, leading to weight loss, dehydration, and ketosis– an omission that has direct
effects on counter-regulation [56,68]. Specifically, in untreated diabetic rats, glucagon, adrenaline, and corticosterone
responses and the subsequent glucose production in hypoglycaemia are reduced compared with normal rats [56,68].
In IAH research, only a few groups have utilised diabetic animal models for their investigation; specifically,
streptozotocin-induced diabetes [56,92,93,95]. Although these studies have increased knowledge in the field, they have
not increased diabetes-specific understanding of IAH. Despite these challenges and a need for optimisation in approach,
replication of nondiabetic model findings in a robust diabetic animal model remains a priority for studies in IAH. We recom-
mend that insulin replacement is used in all animal models of type 1 diabetes to reflect the human condition more
accurately and to minimise confounds related to marked insulin deficiency.
Trends in Endocrinology &Metabolismseveral independent groups have demonstrated effective animal models of IAH and impaired
CRR [39,43,46,51,56,65,69].
In our laboratories, we have elected to model IAH and impaired hypoglycaemia counter-regulation
in Sprague–Dawley rats or C57BL/6 mice. In both rats and mice, the McCrimmon laboratory have
utilised a 4-week protocol of RH (insulin two or three times per week) administered via the IP route
(0.75–1 U/kg in rats and mice and 4 U/kg in streptozotocin-induced type 1 diabetes mice;
Novorapid, NovoNordisk Ltd). The Luckman laboratory have utilised the same 4-week protocol
of RH with insulin administered via the SC route (1.75 U/kg; Humulin S, Eli Lilly). These protocols
consistently impair plasma adrenaline release following the final hypoglycaemic episode compared
with SH ([69,93] and S.M. Luckman et al., unpublished).
Despite the limitations of animal modelling of IAH, important insights can be gained. Recently, using
rodent models, it has been shown that IAH and impaired CRR carry hallmarks of habituation,
a form of biological and cellular adaptation to a repeated stressor (in this case, hypoglycaemia)
[19,69]. These insights, along with others gained from nondiabetic animal models, will need
validation in diabetic models and ultimately patients with IAH.
A driver for this review was a concern that there is a lack of reproducibility of experimental findings
in the field of IAH research. We postulate that much of the variation in reproducibility, both within
and between research groups, is due to real differences in physiology between species.
However, we must also question our own experimental design and whether improved scientific
rigor can increase reproducibility.
Despite a large body of exciting mechanistic research in IAH, key questions remain unanswered
(see Outstanding Questions), and an effective therapy is yet to translate to the clinic. Greater
collaboration between centres with expertise in rodent and human models of IAH, as well as
patients with IAH, is required to gain more translatable insights into this condition. This approach
may also bring consensus in the field over which IAH models to adopt and refine. This will enable
investigators to establish which findings from animal models truly translate to the human condition.
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